# A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.

> **NCT00468897** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** RSG XR

## Key facts

- **NCT ID:** NCT00468897
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03-21
- **Primary completion:** 2007-05-02
- **Final completion:** 2007-05-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00468897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00468897, "A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00468897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*